Creatine is a naturally occurring compound that plays a critical role in cellular energy metabolism. Oral creatine supplementation has been investigated as a neuroprotective strategy for various neurodegenerative disorders[1].
| Property | Value |
|---|---|
| Category | Metabolic Therapy / Neuroprotective |
| Target | Mitochondrial dysfunction, energy depletion |
| Diseases | Huntington's Disease, Parkinson's Disease, ALS |
| Delivery | Oral supplementation |
| Stage | Clinical trials |
Creatine is converted to phosphocreatine (PCr), which serves as an energy reserve for rapid ATP regeneration[1:1]:
Beyond its role in energy metabolism, creatine has been shown to exhibit molecular chaperone-like properties:
| Target | Effect |
|---|---|
| Mitochondrial ATP | Increased PCr/ATP ratio |
| Glutamate receptors | Reduced excitotoxicity |
| ROS production | Decreased oxidative damage |
| BDNF | Potential upregulation |
| Caspase-3 | Inhibition of apoptosis |
| Parameter | Value |
|---|---|
| Bioavailability | >90% |
| Tmax | 1-2 hours |
| Half-life | 3-4 hours |
| Creatine monohydrate | Most studied form |
| Loading dose | 20g/day for 5-7 days |
| Maintenance dose | 3-5g/day |
The CREST-E trial (2015) was the largest randomized controlled trial of creatine in Huntington's disease[3]:
Ongoing studies:
Creatine has shown promise in PD through multiple mechanisms[2:1][4]:
Clinical trials:
Preclinical and clinical evidence supports creatine in ALS[5]:
Current status:
| Compound | Trial | Phase | Indication | Status |
|---|---|---|---|---|
| Creatine | CREST-E | III | Huntington's | Completed |
| Creatine | NCT00463525 | II | Parkinson's | Completed |
| Creatine | BT-1 | II | ALS | Completed |
| Creatine + CoQ10 | NCT04556695 | II | Parkinson's | Recruiting |
| High-dose creatine | NICT-HD | II | Huntington's | Planning |
| Form | Bioavailability | Notes |
|---|---|---|
| Monohydrate | >90% | Standard, well-studied |
| Ethyl ester | Higher | Less water retention |
| Buffered | Similar | Less conversion to creatinine |
| Liquid | Variable | Less stable |
| Population | Safety | Notes |
|---|---|---|
| Healthy adults | Very safe | Extensive safety data |
| Elderly | Safe | Monitor renal function |
| Children | Limited data | Not recommended |
| Pregnancy | Not studied | Avoid |
This combination provides synergistic mitochondrial support[4:2]:
Monitoring creatine supplementation requires specific biomarkers[6]:
| Measure | Frequency | Tool |
|---|---|---|
| Motor function | Monthly | UPDRS, TMT |
| Cognitive function | Monthly | MoCA, SDMT |
| Functional capacity | Quarterly | ADL scales |
| Safety labs | Baseline, 3 months | Renal function |
The study of Creatine Supplementation For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Bender A, et al. Creatine supplementation in neurodegenerative diseases: A therapeutic promise? Nat Rev Neurol. 2008;4(3):140-152. ↩︎ ↩︎ ↩︎
Bender A, et al. Creatine and coenzyme Q10 in the treatment of Huntington's disease: A randomized, double-blind, placebo-controlled trial. J Neurol Sci. 2006;247(1-2):53-58. ↩︎ ↩︎
Hersch SM, et al. The CREST-E study of creatine in Huntington disease: A randomized controlled trial. Neurology. 2015;85(8):713-722. ↩︎
Li M, Chiu JF, Mossman MJ, et al. The effect of creatine and coenzyme Q10 combination therapy on mild cognitive impairment in Parkinson's disease. European Neurology. 2015;73(3-4):205-211. ↩︎ ↩︎ ↩︎
Klivenyi P, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999;5(3):347-350. ↩︎
Beal MF. Neuroprotective effects of high-dose creatine. Ann Neurol. 2001;49(2):260-263. ↩︎